In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the
gastric mucosa. Upon malignant transformation of gastric epithelial tissue, perturbations in cell …

We report interim safety and immunogenicity findings from an ongoing phase 1/2 study of
BNT162b2 in healthy Japanese adults. Participants were randomized 3:1 to receive 2 …

In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses
were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds …

Although pediatric populations experienced lower COVID-19 severity and mortality than adults,
the epidemiology of this disease continues to evolve. COVID-19 clinical manifestations in …

Biomarker-based targeted therapies have changed the cancer treatment paradigm. While
early-stage gastric and gastro-oesophageal junction (GOJ) adenocarcinomas can benefit from …

Background The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18
isoform 2 (CLDN18.2)-positive, human epidermal growth factor receptor 2-negative, locally …

Gastric cancer is the fifth most common malignancy worldwide and one of the main causes
of cancer-related death. While surgical treatment is the only curative option for early disease, …

Background & Aims Although specialized and dedicated to the production of digestive enzymes,
pancreatic acinar cells harbor a high plasticity and are able to modify their identity. They …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious and
pathogenic virus that first appeared in late December 2019. This SARS-CoV-2 causes an …

Background Claudin18. 2 (CLDN18. 2) is a tight junction protein that has been identified as
a clinically proven target in gastric cancer. Stimulation of 4-1BB with agonistic antibodies is …